Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | QPCT | Q16769 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12260350 | 0.85 | ALDH1A1 (0.53) | ALDH1A1LMNAQPCTL3MBTL1MAPT | |
| SCHEMBL28492409 | 0.84 | TBXAS1 (0.53) | ALDH1A1LMNAQPCTL3MBTL1MAPT | |
| SCHEMBL12260313 | 0.82 | ALDH1A1 (0.50) | ALDH1A1LMNAQPCTL3MBTL1MAPT | |
| SCHEMBL14499219 | 0.81 | ALDH1A1 (0.59) | ALDH1A1LMNAL3MBTL1MAPTSMN1; SMN2 | |
| SCHEMBL8429681 | 0.79 | ALDH1A1 (0.61) | ALDH1A1KDM4EHTT | |
| SCHEMBL7006174 | 0.79 | ALDH1A1 (0.66) | ALDH1A1QPCTKDM4E | |
| SCHEMBL20825406 | 0.75 | ALDH1A1 (0.56) | ALDH1A1QPCTKDM4E | |
| SCHEMBL13472650 | 0.74 | KDM4E (0.67) | ALDH1A1QPCTL3MBTL1GAASMN1; SMN2 | |
| SCHEMBL12260560 | 0.73 | ALDH1A1 (0.40) | ALDH1A1LMNAQPCTL3MBTL1MAPT | |
| SCHEMBL806605 | 0.73 | TBXAS1 (0.63) | ALDH1A1QPCTL3MBTL1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190231787-A1 | METHODS AND COMPOUNDS FOR TREATING ALCOHOL USE DISORDERS AND ASSOCIATED DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-08-01 | — | — | US | disclosed |
| WO-2018039641-A1 | METHODS AND COMPOUNDS FOR TREATING ALCOHOL USE DISORDERS AND ASSOCIATED DISEASES | PHARMATROPHIX, INC. (US) | 2018-03-01 | — | — | WO | disclosed |
| US-9464066-B2 | Deuterated compounds useful for treating neurodegenerative diseases | PHARMATROPHIX, INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-9464066-B2 | Deuterated compounds useful for treating neurodegenerative diseases | PHARMATROPHIX, INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-20160229823-A1 | DEUTERATED COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISEASES | Ricerca Biosciences, LLC | 2016-08-11 | — | — | US | disclosed |
| US-20160229823-A1 | DEUTERATED COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISEASES | Ricerca Biosciences, LLC | 2016-08-11 | — | — | US | disclosed |
| US-20120322799-A1 | DEUTERATED COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISEASES | PHARMATROPHIX, INC. (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120322799-A1 | DEUTERATED COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISEASES | PHARMATROPHIX, INC. (US) | 2012-12-20 | — | — | US | disclosed |
| US-20110230479-A1 | NEUROTROPHIN MIMETICS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-09-22 | — | — | US | disclosed |
| US-20110230479-A1 | NEUROTROPHIN MIMETICS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-09-22 | — | — | US | disclosed |
| WO-2010102212-A2 | NEUROTROPHIN MIMETICS AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229823-A1 | DEUTERATED COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISEASES | NLN, NGF, BDNF | ALDH1A1 1744/4885LMNA 2057/4885QPCT 2171/4885 |
| US-20120322799-A1 | DEUTERATED COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISEASES | NLN, NGF, BDNF | ALDH1A1 1744/4885LMNA 2057/4885QPCT 2171/4885 |
| US-20190231787-A1 | METHODS AND COMPOUNDS FOR TREATING ALCOHOL USE DISORDERS AND ASSOCIATED DISEASES | ADH1A, NTRK2, ADH1C | ALDH1A1 82/4885LMNA 1415/4885QPCT 2738/4885 |
| US-20110230479-A1 | NEUROTROPHIN MIMETICS AND USES THEREOF | BDNF, NTRK2, NGF | ALDH1A1 1890/4885LMNA 1601/4885QPCT 3868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.